CONNECT WITH US
HealthTech

HealthTech

MMI raises $125M to scale up in robotic microsurgery

MedTech Dive logo

Published on

Add as a preferred source on Google
MMI raises $125M to scale up in robotic microsurgery

The Symani surgical robot maker said the financing will help broaden adoption of the system in the U.S. and global markets and support a clinical trial for Alzheimer’s disease.

MMI’s Symani system received a de novo classification from the Food and Drug Administration for microsurgery in 2024 and was cleared for use in soft tissue dissection the following year. The robot also has CE mark certification in Europe.

About 3,500 complex microsurgical procedures, such as cancer and trauma-related reconstructive surgeries, have been performed worldwide with Symani, which has an installed base of about 50 systems, the company said.

“We’ve proven there is demand for robotic microsurgery at leading institutions around the world,” MMI CEO Mark Toland said in a statement. “Now, our focus is translating that adoption into scale.”

MMI investor BioStar Capital led the latest financing round, and new investors S3 Ventures, Angelini Ventures and an undisclosed strategic corporate investor participated.

MMI said it plans to invest in areas such as energy instruments and digital surgery capabilities, as well as studies such as REMIND and outcomes data that can expand the applications for Symani.

In the REMIND trial, researchers are investigating the safety and feasibility of using Symani for procedures to restore drainage pathways in the deep cervical lymph nodes of the neck in patients with neurodegenerative disease. The goal is to help clear neurotoxins from the brain thought to contribute to the progression of Alzheimer’s.

The Food and Drug Administration gave MMI the go-ahead this summer to expand enrollment in the study to 15 patients.


Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.